Case of vitiligo universalis as a sequela of drug-induced hypersensitivity syndrome.
autoimmune sequelae
drug-induced hypersensitivity syndrome
human herpesvirus 6
sulfasalazine
vitiligo
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
11
04
2020
revised:
01
07
2020
accepted:
24
07
2020
pubmed:
13
11
2020
medline:
15
5
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
Drug-induced hypersensitivity syndrome (DIHS) is a type of severe drug adverse reaction with high morbidity and mortality. DIHS patients have been reported to subsequently develop autoimmune disease, which may be followed by end-organ decompensation. We report a 47-year-old woman who presented with fever, generalized maculopapular eruption, facial edema and eosinophilia with liver function impairment after taking celecoxib and sulfasalazine for 1 month. The patient was diagnosed with definite DIHS. The patient was treated with immunosuppressants including systemic corticosteroid for approximately 1.5 years due to recurrent episodes. Reactivation of human herpesvirus 6 and possible reactivation of cytomegalovirus were detected. Generalized hypopigmentation of the skin and leukotrichia were noted 4 months after the onset of DIHS. Histopathological examination confirmed the diagnosis of vitiligo. Some spontaneous repigmentation was noted 4 years after DIHS without specific treatment. Further immunoserology study showed elevated plasma C-X-C motif chemokine 10 level, which is related to vitiligo activity, in our patient. The occurrence of widespread vitiligo after DIHS is an extremely rare condition. This case provides an important reminder for physicians to monitor such severe complications after DIHS.
Identifiants
pubmed: 33180345
doi: 10.1111/1346-8138.15562
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-95Informations de copyright
© 2020 Japanese Dermatological Association.
Références
Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006; 55(1): 1-8.
Kano Y, Tohyama M, Aihara M et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol 2015; 42(3): 276-282.
Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15(4): 250-257.
Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156(3): 609-611.
Chen YC, Chang CY, Cho YT et al. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013; 68(3): 459-465.
Iskandarli M, Ozturk G. Alopecia areata and Vitiligo as a long-term sequelae of drug reaction with eosinophilia and systemic symptoms syndrome. Indian J Dermatol 2016; 61(2): 238.
Lonowski S, Hau J, Worswick S. Vitiligo: a potential autoimmune sequela of DRESS syndrome. Br J Dermatol 2016; 175(3): 642-644.
Lian BS, Busmanis I, Lee HY. Relapsing course of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) complicated by alopecia Universalis and Vitiligo. Ann Acad Med Singapore 2018; 47(11): 492-493.
Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 2007; 33(1-2): 124-133.
Takahashi R, Kano Y, Yamazaki Y et al. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182(12): 8071-8079.
Lili Y, Yi W, Ji Y et al. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012; 7(5): e37513.
Harris JE, Harris TH, Weninger W et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol 2012; 132(7): 1869-1876.
Rodrigues M, Ezzedine K, Hamzavi I et al. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 2017; 77(1): 1-13.
Chen CB, Abe R, Pan RY et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res 2018; 2018: 6431694.
Yang L, Wei Y, Sun Y et al. Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in Vitiligo. Acta Derm Venereol 2015; 95(6): 664-670.
Yang CW, Cho YT, Hsieh YC etal. The interferon-γ-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms. Br J Dermatol 2020. https://doi.org/10.1111/bjd.18942